Table 2.
Drug Targeted Delivery System | Cancer Cell Membrane | Targeted Modification | Materials of NPs | Drug-Loading | Cancer Model | Reference |
---|---|---|---|---|---|---|
CCNP | MDA-MB-831cells | No | mPEG-PLGA-NPs | Doxorubicin (DOX) | Brain and metastatic breast cancer | [82] |
CM-NCubes | U-251 MG cells | No | Fe3O4/MnO2- NCubes | Sorafenib and AMF | GBM | [88] |
Dox-CM-BNNTs | U87 MG cells | No | BNNTs | DOX | GBM | [89] |
DHA-NGR/CCNLC | C6 glioma cells | NGR | NLCs | DHA | Glioma | [81] |
WSW-CCM-(PTX)NS | C6 glioma cells | DWSW | PVP K30 and SDC nanosuspension | Paclitaxel (PTX) | Glioma | [87] |
HCPT-NS/CCM | C6 glioma cells | No | Nanosuspension | 10-hydroxycamptothecin (HCPT) | Glioma | [80] |
MnO2-DOX-C6 | C6 glioma cells | No | MnO2 | Doxorubicin (DOX) | Glioma | [85] |
HDX@YSN@CCM@cRGD | U87 MG cells | cRGD | YSNs | Hydroxychloroquine (HDX) | Glioblastoma | [86] |
CC-LnNPs | U87 MG cells | No | LnNPs | No | Glioma | [90] |